BB5523
/ BroadenBio
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 06, 2024
BB5523, a multiple kinase inhibitor with HPK1, VEGFR2 and TNIK inhibition, enhanced antitumor immunity in tumor models
(AACR 2024)
- "As a potent and oral available small molecule kinase inhibitor, BB5523 boosts anti-tumor immunity through HPK1 inhibition, while also blocking crucial signaling pathways in tumor micro-environment. BB5523 shows promising in vitro and in vivo efficacy with a well-tolerated safety profile. The preclinical study of BB5523 is in progress."
Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Hematological Malignancies • Oncology • Solid Tumor • LCP2 • ZAP70
1 to 1
Of
1
Go to page
1